---
title: "Chugai files Japan approval bid for vamikibart in non-infectious uveitic macular edema"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296868472.md"
description: "Chugai Pharmaceutical has filed for Japanese regulatory approval of vamikibart to treat uveitic macular edema associated with non-infectious uveitis. The submission is supported by global Phase 3 MEERKAT and SANDCAT trial results. Notably, Japan’s health ministry granted orphan drug designation for this indication on June 23, 2026."
datetime: "2026-08-25T06:36:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296868472.md)
  - [en](https://longbridge.com/en/news/296868472.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296868472.md)
generator: "portal-rs"
---

# Chugai files Japan approval bid for vamikibart in non-infectious uveitic macular edema

-   Chugai filed for Japanese regulatory approval of vamikibart to treat uveitic macular edema linked to non-infectious uveitis. \* Japan’s health ministry granted orphan drug designation for the indication on June 23, 2026. \* Submission supported by global Phase 3 MEERKAT and SANDCAT trial results. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CHGCY.US](https://longbridge.com/en/quote/CHGCY.US.md)
- [4519.JP](https://longbridge.com/en/quote/4519.JP.md)

## Related News & Research

- [Chugai files Japan application for Tecentriq as adjuvant MSI-high colon cancer treatment](https://longbridge.com/en/news/295890880.md)
- [Chugai seeks Japan approval for Enspryng to prevent MOGAD relapses](https://longbridge.com/en/news/294463834.md)
- [Pfizer EVP Cecile Guegan files initial beneficial ownership statement](https://longbridge.com/en/news/297360414.md)
- [DBJ report sees Japan-wide spillovers of 2.1 trillion yen from Shunan complex decarbonization capex](https://longbridge.com/en/news/297268115.md)
- [FS Bancorp director Terri Degner sells 1,693 shares worth $72,763.37](https://longbridge.com/en/news/297347836.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**